Neoplastic Cells, Circulating

• 

  Subject Areas on Research

  • 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • Accuracy in staging of renal cell carcinoma involving vena cava. 
  • Acoustic separation of circulating tumor cells. 
  • Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection. 
  • Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. 
  • Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. 
  • Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma. 
  • Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. 
  • Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. 
  • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. 
  • Cases from the Osler Medical Service at Johns Hopkins University. 
  • Caval thrombosis: imaging and managing a moving target. 
  • Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. 
  • Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. 
  • Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. 
  • Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. 
  • Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us. 
  • Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. 
  • Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. 
  • Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. 
  • Circulating tumor cell analysis in metastatic triple-negative breast cancers. 
  • Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. 
  • Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential. 
  • Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. 
  • Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. 
  • Circulating tumor cells in melanoma patients. 
  • Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. 
  • Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. 
  • Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. 
  • Clinical utility of non-EpCAM based circulating tumor cell assays. 
  • Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. 
  • Computational models of cancer cell transport through the microcirculation. 
  • Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. 
  • Detection of cerebrospinal fluid metastasis: CT myelography or MR? 
  • Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. 
  • Development of a Novel c-MET-Based CTC Detection Platform. 
  • Development of a method to isolate circulating tumor cells using mesenchymal-based capture. 
  • Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. 
  • Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. 
  • Does transurethral resection of the prostate promote metastatic disease? 
  • Dual-Energy Multidetector Computed Tomography With Iodine Quantification in the Evaluation of Portal Vein Thrombosis: Is It Possible to Discard the Unenhanced Phase? 
  • Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). 
  • Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells. 
  • Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. 
  • Fine-needle aspiration of inflammatory carcinoma of the breast. 
  • Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis. 
  • Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. 
  • Imaging and Isolation of Extravasation-Participating Endothelial and Melanoma Cells During Angiopellosis. 
  • Improving sensitivity and specificity of capturing and detecting targeted cancer cells with anti-biofouling polymer coated magnetic iron oxide nanoparticles. 
  • In vivo label-free photoacoustic flow cytography and on-the-spot laser killing of single circulating melanoma cells. 
  • Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. 
  • Influence of trauma on the unusual distribution of metastases from carcinoma of the larynx. 
  • Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis. 
  • Making progress on progression in metastatic prostate cancer. 
  • Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. 
  • MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. 
  • Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience. 
  • Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. 
  • NanoVelcro Chip for CTC enumeration in prostate cancer patients. 
  • Necrosis and apoptosis of tumor cells in embolized meningiomas: histopathology and P53, BCL-2, CD-68 immunohistochemistry. 
  • Normothermic cardiopulmonary bypass with beating heart for management of renal cell carcinoma with atrial tumor thrombus. 
  • PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 
  • Partners in Crime: Neutrophil-CTC Collusion in Metastasis. 
  • Personalized treatment of lung cancer. 
  • Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. 
  • Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. 
  • Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars. 
  • Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 
  • Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients. 
  • Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. 
  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. 
  • Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. 
  • Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. 
  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. 
  • Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. 
  • Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. 
  • Regional spread of cutaneous squamous cell carcinoma of the face via facial vein tumor thrombus: a case report. 
  • Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. 
  • Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. 
  • Renal carcinoma: detection of venous extension with gradient-echo MR imaging. 
  • Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. 
  • Role of deformable cancer cells on wall shear stress-associated-VEGF secretion by endothelium in microvasculature. 
  • Routine use of zoledronic acid in early-stage breast cancer. 
  • Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. 
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. 
  • Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. 
  • Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. 
  • Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. 
  • Surgical management and prognosis of renal cell carcinoma invading the vena cava. 
  • Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. 
  • Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. 
  • Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. 
  • Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. 
  • Using circulating tumor cells to inform on prostate cancer biology and clinical utility. 
  • Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. 
• 

  Keywords of People

  • Bitting, Rhonda L, Associate Professor of Medicine, Medicine, Medical Oncology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology